Xacduro (sulbactam, durlobactam)
Research Synopsis
- - Research on Xacduro (sulbactam, durlobactam) indicates it is an effective treatment option for infections caused by multidrug-resistant bacteria, particularly Acinetobacter baumannii.
- - The drug demonstrates enhanced antibacterial activity compared to sulbactam alone, making it a promising candidate against carbapenem-resistant bacterial infections.
- - A study on pharmacokinetics revealed that renal impairment affects the drug's levels but retains a consistent safety profile across different patient groups with varying kidney functions.
- - Clinical trials show that sulbactam/durlobactam has a favorable tolerability and effectiveness profile when combined with other antibiotics, particularly in cases of complicated urinary tract infections.
- - Efficacy studies have demonstrated strong performance against global Acinetobacter baumannii isolates, indicating a broad spectrum of activity across different strains and resistance patterns.
- - Research highlights that the combination can overcome resistance mechanisms often seen in bacterial strains, increasing the chances of successful treatment outcomes for critically ill patients.
- - In the ATTACK trial, sulbactam-durlobactam not only met primary effectiveness goals against antibiotic-resistant strains but also presented a better safety profile compared to traditional treatments like colistin.
- - Systematic reviews find a low resistance rate (approximately 2.3%) to sulbactam/durlobactam; however, higher resistance is noted in certain strains such as metallo β-lactamase producers.
- - Overall, these findings suggest that sulbactam/durlobactam is a significant advancement in addressing the challenge of antibiotic resistance, although ongoing research and clinical evaluations are crucial for establishing its full clinical potential.
Xacduro (sulbactam, durlobactam)
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
London, UK
2 hours ago
1 Received
- Sulbactam-durlobactam is being tested for treating infections resistant to multiple drugs, including carbapenems, and this study focused on how renal impairment affects the drugs' pharmacokinetics and safety.
- The study involved administering different doses of durlobactam and sulbactam to subjects with varying levels of kidney function, including end-stage renal disease (ESRD) patients on hemodialysis.
- Findings showed that reduced kidney function led to higher drug levels in the body, but the safety profile remained similar across all groups, and results will help determine appropriate dosages for patients with kidney issues.
$100 - $150
Hourly Rate
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
London, UK
2 hours ago
1 Received
- Durlobactam (DUR) is a new β-lactamase inhibitor that enhances the effectiveness of sulbactam (SUL) against certain resistant infections known as the -complex (ABC).
- A study involved 80 patients with complicated urinary tract infections (cUTIs) who received either SUL-DUR or a placebo alongside imipenem-cilastatin (IMI) for 7 days, assessing the drug's tolerability and pharmacokinetics.
- Results showed SUL-DUR was well tolerated with minimal adverse effects, and its effectiveness was comparable to that of the placebo group when combined with IMI, indicating potential for treating cUTIs.
$100 - $150
Hourly Rate
Activity of Sulbactam-Durlobactam against Acinetobacter baumannii- Complex Isolates Collected Globally in 2016 and 2017.
London, UK
2 hours ago
1 Received
- - Sulbactam-durlobactam (SUL-DUR) is an antibiotic designed to effectively treat severe infections caused by complex organisms that are often resistant to multiple drugs, particularly multidrug-resistant strains.
- - In testing against 1,722 clinical isolates from various regions, SUL-DUR showed significantly better antibacterial activity compared to sulbactam alone, and its efficacy was consistent across different types of infections and resistance patterns.
- - Whole-genome sequencing of a small percentage of isolates with reduced effectiveness revealed specific resistance factors, indicating potential challenges in treating certain strains, but overall, SUL-DUR remains a powerful option against recent and diverse infections.
$100 - $150
Hourly Rate
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.
London, UK
2 hours ago
1 Received
- Durlobactam is an inhibitor of various β-lactamases and, when added to sulbactam, enhances the treatment of infections caused by the resistant bacteria Acinetobacter baumannii.
- A study investigated the effectiveness of the sulbactam/durlobactam combination on A. baumannii isolates from patients in China, as previous data mainly came from Western countries.
- The findings revealed that sulbactam/durlobactam significantly improved antimicrobial activity against A. baumannii strains, demonstrating potential for treating infections in that region.
$100 - $150
Hourly Rate
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
London, UK
2 hours ago
1 Received
- This study aimed to assess the effectiveness of a new broad-spectrum drug (durlobactam) combined with sulbactam against tough strains of carbapenem-resistant Acinetobacter baumannii collected globally.
- Researchers tested 246 unique bacterial samples from different patients and countries, comparing how these strains responded to sulbactam/durlobactam and several other antibiotics.
- Results showed that the sulbactam/durlobactam combo was highly effective, outperforming several other antibiotics, making it a promising option for treating infections caused by resistant A. baumannii.
$100 - $150
Hourly Rate
New β-Lactam-β-Lactamase Inhibitor Combinations.
London, UK
2 hours ago
1 Received
- Research on drug-resistant Gram-negative bacteria has led to new combinations of β-lactam antibiotics and β-lactamase inhibitors (BLBLIs), which aim to combat multidrug-resistant (MDR) infections.
- The review provides details on four approved BLBLIs—Ceftazidime-avibactam, Ceftolozane-tazobactam, Meropenem-vaborbactam, and Imipenem-relebactam—including their effectiveness against various β-lactamase producing strains and their pharmacokinetic properties.
- Although these drugs show promise, especially against certain resistant bacteria, clinical data is limited and mostly comes from nonrandomized studies, highlighting the need for further research and development
$100 - $150
Hourly Rate
Antibacterial Activity and Efficacy of Sulbactam-Durlobactam against Pathogenic Species.
London, UK
2 hours ago
1 Received
- The text discusses the challenges posed by hard-to-treat Gram-negative bacterial pathogens, including species causing glanders and melioidosis, as well as those linked to lung infections in cystic fibrosis patients.
- It highlights the clinical development of a new β-lactam-β-lactamase inhibitor combination called sulbactam-durlobactam (SUL-DUR), which shows promise against these resistant infections.
- The study reveals that SUL-DUR effectively inhibits a majority of targeted bacterial strains and demonstrates potential efficacy in mouse models, suggesting it could be a viable treatment option for severe infections caused by these pathogens.
$100 - $150
Hourly Rate
In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Infections in Combination With Sulbactam.
London, UK
2 hours ago
1 Received
- Durlobactam is a new β-lactamase inhibitor that works against a wide range of resistant bacteria, specifically targeting Ambler class A, C, and D enzymes.
- Sulbactam, an older β-lactamase inhibitor, has limited effectiveness due to its vulnerability against many β-lactamases, but it also directly fights certain bacteria by disrupting their cell wall synthesis.
- Combining sulbactam with durlobactam enhances sulbactam's effectiveness against multidrug-resistant infections, particularly those caused by carbapenem-resistant bacteria, and is currently being advanced for clinical use.
$100 - $150
Hourly Rate
Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.
London, UK
2 hours ago
1 Received
- XDR Acinetobacter baumannii is a highly resistant bacteria that causes difficult hospital-acquired infections.
- A specific case involved a patient with XDR A. baumannii pneumonia and septic shock, who was treated successfully with cefiderocol and a new antibiotic through an expanded access program.
- Increased research and development of drugs can help improve the outcomes for patients facing these challenging infections.
$100 - $150
Hourly Rate
Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections.
London, UK
2 hours ago
1 Received
- Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are difficult to manage, leading to unfavorable patient outcomes.
- A recent study demonstrated that the combination of sulbactam-durlobactam and cefiderocol effectively treats CRAB pneumonia.
- Despite these promising results, more detailed randomized controlled trials are necessary to find the best treatment strategies for CRAB infections.
$100 - $150
Hourly Rate
Genome sequencing and molecular characterisation of XDR Acinetobacter baumannii reveal complexities in resistance: Novel combination of sulbactam-durlobactam holds promise for therapeutic intervention.
London, UK
2 hours ago
1 Received
- Emerging strains of Acinetobacter baumannii are showing high levels of drug resistance (XDR), with 92.86% of Indian isolates carrying carbapenemase genes that lead to sulbactam resistance.* -
- The predominant lineage identified was IC2/CC2, making up 57.14% of the isolates, with dual carbapenemase genes found in over a third of them.* -
- The study highlights the potential of a novel treatment strategy using durlobactam, which demonstrates strong interactions with carbapenemases and may restore the effectiveness of sulbactam against these resistant strains.*
$100 - $150
Hourly Rate
Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Isolates From Greece.
London, UK
2 hours ago
1 Received
- Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major cause of healthcare-associated infections worldwide, driven by its ability to resist current antibiotics and the need for new treatment options.
- A new drug combination, sulbactam-durlobactam (SD), has shown promise by restoring the activity of sulbactam against these resistant strains.
- In a study involving 190 CRAB isolates from Greek hospitals, SD demonstrated significantly lower minimum inhibitory concentrations (MICs) compared to other treatments, indicating its potential as an effective option for treating CRAB infections.*
$100 - $150
Hourly Rate
Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Novel Combination Therapy for Extensively Drug-Resistant Necrotizing Pneumonia Complicated by Empyema: A Case Report.
London, UK
2 hours ago
1 Received
- A 50-year-old patient in Detroit had severe, hard-to-treat necrotizing pneumonia with empyema, putting them in critical condition.* ! -
- The treatment utilized a precision medicine strategy that included whole-genome sequencing and susceptibility testing to identify the best medications.* ! -
- By analyzing drug interactions and using combination therapy, healthcare providers aimed to effectively combat the patient's extensively drug-resistant infection.* !
$100 - $150
Hourly Rate
In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant Clinical Isolates: A Multicentre Report from Italy.
London, UK
2 hours ago
1 Received
- * More than half of the tested bacterial isolates (54.6%) showed resistance to the antibiotic colistin, but the SUL-DUR combo was mostly effective with low minimum inhibitory concentration (MIC) values.
- * The research found that only a small number of the isolates (11) were resistant to SUL-DUR, which carried various resistance genes and mutations, marking it as the first study to report on the antimicrobial activity of SUL-DUR against these tough-to-treat infections
$100 - $150
Hourly Rate
In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance.
London, UK
2 hours ago
1 Received
- * This study assessed the effectiveness of the drug combination sulbactam (SUL) and durlobactam (DUR) against carbapenemase-producing A. baumannii, utilizing methods like susceptibility testing and whole genome sequencing to investigate resistance mechanisms.
- * Results showed that SUL-DUR demonstrated strong antibacterial activity, with 71% efficacy against tested isolates, while identifying specific genetic mutations in penicillin-binding proteins that may contribute to resistance in 25 SUL-DUR resistant isolates. *
$100 - $150
Hourly Rate
Activity of Sulbactam-Durlobactam against Global Isolates of - Complex Collected from 2016 to 2021.
London, UK
2 hours ago
1 Received
- Sulbactam-durlobactam is a combination drug effective against serious infections from Acinetobacter baumannii complex (ABC), particularly multidrug-resistant strains.
- A study tested this drug on 5,032 ABC isolates from various global regions between 2016 and 2021, finding it significantly reduces the minimum inhibitory concentration (MIC) of sulbactam.
- The treatment was effective against 98.3% of isolates, including those resistant to multiple antibiotics, with a majority of the tested strains being susceptible to sulbactam-durlobactam.
$100 - $150
Hourly Rate
Resistance to Sulbactam/Durlobactam: A Systematic Review.
London, UK
2 hours ago
1 Received
- * A systematic review analyzed 10 in vitro studies examining resistance to sulbactam/durlobactam, finding that overall, 2.3% of tested isolates were resistant.
- * Notably, resistance was observed to be higher in specific groups like CRAB and colistin-resistant strains, with metallo β-lactamase-producing strains showing 100% resistance, highlighting a limited effectiveness of the drug against those particular strains.
$100 - $150
Hourly Rate
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.
London, UK
2 hours ago
1 Received
- There’s a growing need for new antibiotics to combat antimicrobial resistance, especially against tough gram-negative bacteria like Acinetobacter baumannii.* -
- Sulbactam-durlobactam (SUL-DUR) is a promising antibiotic designed to specifically target drug-resistant strains of ABC and has shown positive results in the ATTACK trial, which compared its effectiveness to colistin.* -
- SUL-DUR not only met the key effectiveness goal but also demonstrated a better safety profile, suggesting it could become a crucial treatment for serious infections caused by resistant ABC strains if approved.*
$100 - $150
Hourly Rate